Video

Making Decisions on Bladder Removal

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man.
Understanding Unique Treatment Options Across Bladder Cancer Care
Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment plan.
A Personalized Approach to Bladder Preservation in Urologic Cancers
Image of doctor.
Patient and Disease-Related Factors Influence Outcomes in Urothelial Cancer
Image of man.
Understanding the FDA Imfinzi Combo Approval for Bladder Cancer Care
Image of man with black hair.
Bavencio Maintains Bladder Cancer Benefit in Patients with Diabetes
Image of man.
Dr. Grivas Highlights Three Practice-Changing Trials in Bladder Cancer
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Better Understanding Genetic Mutations Influence in Cancer Care
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
An Expert Highlights His Key Takeaways From The 2025 ASCO GU Symposium
Image of man with black hair.
Personalized Medicine Makes Strides Across the GU Oncology Treatment Space
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
An Expert Breaks Down the Effect of Diabetes on Urothelial Cancer Treatment
Related Content
Antihistamines may be associated with survival improvement in patients with metastatic urothelial carcinoma receiving Tecentriq: © stock.adobe.com
May 30th 2025

Additive Antihistamines May Improve Metastatic Bladder Cancer Outcomes

Alex Biese
Antihistamines may be associated with survival improvement in patients with metastatic urothelial carcinoma receiving Tecentriq.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Aidixi plus toripalimab met study end points for patients with HER2-expressing urothelial carcinoma: © stock.adobe.com.
May 14th 2025

Aidixi Combination Therapy Improves Survival in Urothelial Carcinoma

Spencer Feldman
Aidixi plus toripalimab met progression-free and overall survival study end points versus chemo for patients with HER2-expressing urothelial carcinoma.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Imfinzi plus BCG induction and maintenance statistically and clinically meaningfully improved DFS in some with bladder cancer: © stock.adobe.com.
May 9th 2025

Imfinzi Regimen Improves Disease-Free Survival in Early Bladder Cancer

Spencer Feldman
Imfinzi plus BCG induction and maintenance therapy showed a statistically and clinically meaningful improvement in DFS for some with bladder cancer.
Image of bladder.
April 30th 2025

Aidixi Plus Bacillus Calmette-Guérin Effective in Bladder Cancer

Jason M Broderick
Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing non–muscle-invasive bladder cancer.